RxSight Beheer
Beheer criteriumcontroles 3/4
De CEO RxSight is Ron Kurtz, benoemd in Jan2016, heeft een ambtstermijn van 8.92 jaar. De totale jaarlijkse vergoeding van { bedraagt $ 3.08M, bestaande uit 20.6% salaris en 79.4% bonussen, inclusief aandelen en opties van het bedrijf. bezit rechtstreeks 2.05% van de aandelen van het bedrijf, ter waarde $ 37.96M. De gemiddelde ambtstermijn van het managementteam en de raad van bestuur bedraagt respectievelijk 4.2 jaar en 3.3 jaar.
Belangrijke informatie
Ron Kurtz
Algemeen directeur
US$3.1m
Totale compensatie
| Percentage CEO-salaris | 20.6% |
| Dienstverband CEO | 8.9yrs |
| Eigendom CEO | 2.1% |
| Management gemiddelde ambtstermijn | 4.2yrs |
| Gemiddelde ambtstermijn bestuur | 3.3yrs |
Recente managementupdates
Recent updates
RxSight's Momentum In The Large Cataract Surgery Market Merits A Close Eye
Nov 29We Think RxSight (NASDAQ:RXST) Can Easily Afford To Drive Business Growth
Sep 04
Investing In The Future Of Cataract Surgery: The RxSight Advantage
Aug 13With A 27% Price Drop For RxSight, Inc. (NASDAQ:RXST) You'll Still Get What You Pay For
Aug 03Why RxSight, Inc. (NASDAQ:RXST) Could Be Worth Watching
Jul 12RxSight: Great Business Model, Stretched Valuations
Jul 10A Look At The Intrinsic Value Of RxSight, Inc. (NASDAQ:RXST)
Jun 20RxSight, Inc. (NASDAQ:RXST) Analysts Are Pretty Bullish On The Stock After Recent Results
May 09RxSight (NASDAQ:RXST) Is In A Strong Position To Grow Its Business
May 05RxSight: Promising Technology, Uncertain Profitability - A Hold Recommendation
May 01Why We're Not Concerned About RxSight, Inc.'s (NASDAQ:RXST) Share Price
Apr 16Is It Time To Consider Buying RxSight, Inc. (NASDAQ:RXST)?
Mar 24RxSight Stock: Time To Refocus Following Eye Watering Rally
Jan 16RxSight, Inc. (NASDAQ:RXST) Stocks Shoot Up 30% But Its P/S Still Looks Reasonable
Jan 09We Think RxSight (NASDAQ:RXST) Can Afford To Drive Business Growth
Dec 21Revenues Tell The Story For RxSight, Inc. (NASDAQ:RXST) As Its Stock Soars 28%
Nov 24RxSight, Inc. (NASDAQ:RXST) Just Reported And Analysts Have Been Lifting Their Price Targets
Aug 11RxSight Non-GAAP EPS of -$0.50 beats by $0.15, revenue of $11.4M beats by $0.85M
Aug 08RxSight says FDA requires additional info for approval of light delivery device
Jul 12Analyse CEO-vergoeding
| Datum | Totale vergoeding | Salaris | Bedrijfswinsten |
|---|---|---|---|
| Sep 30 2024 | n/a | n/a | -US$31m |
| Jun 30 2024 | n/a | n/a | -US$37m |
| Mar 31 2024 | n/a | n/a | -US$44m |
| Dec 31 2023 | US$3m | US$633k | -US$49m |
| Sep 30 2023 | n/a | n/a | -US$55m |
| Jun 30 2023 | n/a | n/a | -US$59m |
| Mar 31 2023 | n/a | n/a | -US$62m |
| Dec 31 2022 | US$1m | US$563k | -US$67m |
| Sep 30 2022 | n/a | n/a | -US$67m |
| Jun 30 2022 | n/a | n/a | -US$63m |
| Mar 31 2022 | n/a | n/a | -US$59m |
| Dec 31 2021 | US$5m | US$445k | -US$49m |
| Sep 30 2021 | n/a | n/a | -US$15m |
| Jun 30 2021 | n/a | n/a | US$4m |
| Mar 31 2021 | n/a | n/a | US$17m |
| Dec 31 2020 | US$741k | US$310k | US$3m |
Compensatie versus markt: De totale vergoeding ($USD 3.08M ) Ron } ligt onder het gemiddelde voor bedrijven van vergelijkbare omvang in de US markt ($USD 5.36M ).
Compensatie versus inkomsten: De vergoeding van Ron is gestegen terwijl het bedrijf verliesgevend is.
CEO
Ron Kurtz (61 yo)
8.9yrs
Tenure
US$3,081,597
Compensatie
Dr. Ronald M. Kurtz, also known as Ron, M.D., serves as President and Chief Executive Officer at RxSight, Inc. (formerly Calhoun Vision) since January 2016 and also serves as its Director since February 20...
Leiderschapsteam
| Naam | Positie | Tenure | Compensatie | Eigendom |
|---|---|---|---|---|
| President | 8.9yrs | US$3.08m | 2.05% $ 38.0m | |
| Co-President & Chief Commercial Officer | 9.5yrs | US$1.65m | 0.76% $ 14.1m | |
| Co-President & Chief Financial Officer | 7.8yrs | US$1.89m | 0.076% $ 1.4m | |
| Co-President & Chief Operating Officer | 5.5yrs | US$1.89m | 0.11% $ 2.0m | |
| Vice President of Accounting & Finance | no data | geen gegevens | geen gegevens | |
| Chief Technology Officer | no data | geen gegevens | geen gegevens | |
| Vice President of Investor Relations | 1.1yrs | geen gegevens | geen gegevens | |
| Senior VP of Sales of North America | less than a year | geen gegevens | geen gegevens | |
| Senior VP of Marketing & Professional Relations | 2.9yrs | geen gegevens | geen gegevens | |
| Vice President of Human Resources | 9.3yrs | geen gegevens | geen gegevens | |
| Executive VP of Manufacturing & Commercial Operations | 2.9yrs | geen gegevens | geen gegevens | |
| Executive VP of Clinical & Regulatory Affairs | 2.8yrs | geen gegevens | geen gegevens |
4.2yrs
Gemiddelde duur
62yo
Gemiddelde leeftijd
Ervaren management: Het managementteam van RXST wordt beschouwd als ervaren (gemiddelde ambtstermijn 4.2 jaar).
Bestuursleden
| Naam | Positie | Tenure | Compensatie | Eigendom |
|---|---|---|---|---|
| President | 8.8yrs | US$3.08m | 2.05% $ 38.0m | |
| Director | 8.1yrs | US$204.98k | 0.11% $ 2.1m | |
| Independent Director | 3.3yrs | US$209.98k | 0.062% $ 1.2m | |
| Independent Director | 9.5yrs | US$209.98k | 0.090% $ 1.7m | |
| Independent Chairman of the Board | 9.9yrs | US$257.48k | 1.33% $ 24.6m | |
| Independent Director | 2.9yrs | US$204.98k | 0.057% $ 1.0m | |
| Independent Director | 3.3yrs | US$214.98k | 0.062% $ 1.2m | |
| Independent Director | 3.3yrs | US$212.48k | 0.062% $ 1.2m | |
| Independent Director | 3yrs | US$199.98k | 0.0048% $ 89.4k |
3.3yrs
Gemiddelde duur
61yo
Gemiddelde leeftijd
Ervaren bestuur: De raad van bestuur van RXST wordt beschouwd als ervaren (gemiddelde ambtstermijn 3.3 jaar).